Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The study ran for 48 weeks, providing substantial follow-up to assess both efficacy and the durability of blood sugar improvements
Load your plate with nonstarchy veggies (leafy greens, broccoli, cauliflower, peppers)
placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
The procedure is entirely painless and involves very little discomfort or recovery
